Form 4: Abbott Laboratories Director Daniel J. Starks Reports Stock and Option Awards

Director Daniel J. Starks reports acquisition of restricted stock units and stock options in Abbott Laboratories under the 2017 Incentive Stock Program.

Summary

• Daniel J. Starks, a director at Abbott Laboratories, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On April 26, 2024, Starks acquired 1,866 common shares in the form of restricted stock units under the Abbott Laboratories 2017 Incentive Stock Program.
• These restricted stock units will be paid out in Abbott common shares on a one-to-one basis upon separation from service, death, or a change in control.
• Starks also acquired 5,277 stock options with an exercise price of $107.14, exercisable from April 26, 2024, and expiring on April 25, 2034.
• The report also indicates that Starks indirectly owns 258 common shares through the Alynne Starks 2012 Irrevocable Trust, for which he serves as the sole trustee.
• Following these transactions, Starks directly owns 5,277 derivative securities and 6,727,182 common shares, and indirectly owns 258 common shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document is a standard regulatory filing reporting stock and option awards. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider transactions.

Positives

• The acquisition of restricted stock units and stock options by a director signals confidence in the company's future performance.
• The incentive stock program aligns the director's interests with those of the shareholders.

Future Outlook

The restricted stock units will be paid out in Abbott common shares upon separation from service, death, or a change in control, as defined in the Program.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their company's stock. These filings are closely monitored by investors to gauge insider sentiment and potential future performance.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in publicly traded companies like Abbott Laboratories.
• Companies such as Johnson & Johnson (JNJ) and Medtronic (MDT) also utilize similar incentive programs to align executive compensation with shareholder value.
• The specific terms of these grants, such as vesting schedules and exercise prices, are typically benchmarked against industry peers to ensure competitiveness.

Stakeholder Impact

• The stock and option awards align the director's interests with those of the shareholders, potentially driving long-term value creation.
• The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates